FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056377426> ?p ?o ?g. }

• W2056377426 endingPage "28292" @default.
• W2056377426 startingPage "28286" @default.
• W2056377426 abstract "12-O-tetradecanoylphorbol-13-acetate (TPA), a phorbol ester that is known as a tumor promoter, induces differentiation of myeloid cells and suppresses their proliferation. We studied the regulation of apoptosis by TPA in human monocytic cell line U937 cells that lack p53. Untreated U937 cells constitutively underwent apoptosis, and TPA enhanced apoptosis in these cells. Further studies showed that TPA increased production of tumor necrosis factor-α (TNFα) in U937 cells, and exogenously added TNFα induced apoptosis. Moreover, the induction of apoptosis by TPA was blocked by anti-TNFα antibody. Similar results were obtained in the myeloblastic cell line KY821 cells. We also found that the induction of apoptosis by TPA was increased in cells overexpressed with TNF receptor 1 but not in control cells. Furthermore, TPA failed to induce the production of TNFα and apoptosis in cells with either their protein kinase C or mitogen-activated protein kinase pathway blocked. Our results indicate that TPA induces apoptosis, at least in part, through a pathway that requires endogenous production of TNFα in U937 cells. Our data also suggest that the induction of apoptosis by TPA occurs through activation of protein kinase C and mitogen-activated protein kinase and TNFα is an autocrine-stimulating factor for the induction of apoptosis in these cells. 12-O-tetradecanoylphorbol-13-acetate (TPA), a phorbol ester that is known as a tumor promoter, induces differentiation of myeloid cells and suppresses their proliferation. We studied the regulation of apoptosis by TPA in human monocytic cell line U937 cells that lack p53. Untreated U937 cells constitutively underwent apoptosis, and TPA enhanced apoptosis in these cells. Further studies showed that TPA increased production of tumor necrosis factor-α (TNFα) in U937 cells, and exogenously added TNFα induced apoptosis. Moreover, the induction of apoptosis by TPA was blocked by anti-TNFα antibody. Similar results were obtained in the myeloblastic cell line KY821 cells. We also found that the induction of apoptosis by TPA was increased in cells overexpressed with TNF receptor 1 but not in control cells. Furthermore, TPA failed to induce the production of TNFα and apoptosis in cells with either their protein kinase C or mitogen-activated protein kinase pathway blocked. Our results indicate that TPA induces apoptosis, at least in part, through a pathway that requires endogenous production of TNFα in U937 cells. Our data also suggest that the induction of apoptosis by TPA occurs through activation of protein kinase C and mitogen-activated protein kinase and TNFα is an autocrine-stimulating factor for the induction of apoptosis in these cells. Apoptosis, a morphologically distinguished form of programmed cell death, plays important roles not only during development and tissue homeostasis but also in the pathogenesis of a variety of diseases including cancer, autoimmune disease, viral infection, and neurodegenerative disorder (1Raff M.C. Nature. 1992; 356: 397-400Crossref PubMed Scopus (2488) Google Scholar, 2Williams G.T. Smith C.A. Cell. 1993; 74: 777-779Abstract Full Text PDF PubMed Scopus (903) Google Scholar, 3Fisher D.E. Cell. 1994; 78: 539-542Abstract Full Text PDF PubMed Scopus (1368) Google Scholar, 4Martin S.J. Green D.R. Crit. Rev. Oncol. Hematol. 1995; 18: 137-153Crossref PubMed Scopus (154) Google Scholar, 5Thompson C.B. Science. 1995; 267: 1456-1462Crossref PubMed Scopus (6174) Google Scholar, 6White E. Genes Dev. 1996; 10: 1-15Crossref PubMed Scopus (1322) Google Scholar). Moreover, various chemicals and drugs for treatment of cancers are known to destroy tumor cells through apoptosis (7Eastman A. Curr. Opin. Oncol. 1990; 2: 1109-1114Crossref PubMed Scopus (11) Google Scholar, 8Miyashita T. Reed J.C. Blood. 1993; 81: 151-157Crossref PubMed Google Scholar). The precise mechanisms that control apoptosis have not been elucidated; it appears that this form of cell death is regulated by a genetic program involving both inducers and repressors (6White E. Genes Dev. 1996; 10: 1-15Crossref PubMed Scopus (1322) Google Scholar). The tumor suppressor p53 is one of the key proteins affecting the fate of cells exposed to external insults; activation of p53 leads to apoptosis or cell cycle arrest. Inactivation of p53 by either a mutation of the gene or interaction with oncogenic viral or cellular proteins is a common event in the development of malignancies (9Nigro J.M. Baker S.J. Preisinger A.C. Jessup J.M. Hostetter R. Cleary K. Bigner S.H. Davidson N. Baylin S. Devilee P. Glover T. Collins F.S. Weston A. Modali R. Harris C.C. Vogelstein B. Nature. 1989; 342: 705-708Crossref PubMed Scopus (2553) Google Scholar). On the other hand, recent studies have found pathways of apoptosis independent of p53 (10Yonish-Rouach E. Experientia. 1996; 52: 1001-1007Crossref PubMed Scopus (57) Google Scholar).Protein kinase C (PKC) 1The abbreviations used are:PKCprotein kinase CTPA12-O-tetradecanoylphorbol-13-acetateTNFαtumor necrosis factor-αIL-1βinterleukin-1βTNFR1TNF receptor 1MAPKmitogen-activated protein kinaseERKextracellular signal-regulated protein kinaseMEKmitogen-activated/extracellular-regulated kinasekbkilobase(s)SPPsphingosine-1-phosphateRbretinoblastoma susceptibility gene product 1The abbreviations used are:PKCprotein kinase CTPA12-O-tetradecanoylphorbol-13-acetateTNFαtumor necrosis factor-αIL-1βinterleukin-1βTNFR1TNF receptor 1MAPKmitogen-activated protein kinaseERKextracellular signal-regulated protein kinaseMEKmitogen-activated/extracellular-regulated kinasekbkilobase(s)SPPsphingosine-1-phosphateRbretinoblastoma susceptibility gene product plays important roles in physiological events such as cell differentiation and proliferation (11Weinstein I.B. Cancer Res. 1988; 48: 4135-4143PubMed Google Scholar). PKC phosphorylates and activates Raf-1, which leads to the activation of mitogen-activated protein kinase (MAPK) or extracellular signal-regulated protein kinase (ERK) (12Kolch W. Heidecker G. Kochs G. Hummel R. Vahidi H. Mischak H. Finkenzeller G. Marme D. Rapp U.R. Nature. 1993; 364: 249-252Crossref PubMed Scopus (1153) Google Scholar). By contrast, studies have shown that proliferation of cells is also inhibited by PKC activation; phorbol esters that can activate PKC have been shown to inhibit the phosphorylation of retinoblastoma susceptibility gene product (Rb) (13Sasaguri T. Ishida A. Kosaka C. Nojima H. Ogata J. J. Biol. Chem. 1996; 271: 8345-8351Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar). 12-O-tetradecanoylphorbol-13-acetate (TPA) is a novel activator of PKC; previous studies (14de Vente J.E. Kukoly C.A. Bryant W.O. Posekany K.J. Chen J. Fletcher D.J. Parker P.J. Pettit G.J. Lozano G. Cook P.P. Ways D.K. J. Clin. Invest. 1995; 96: 1874-1886Crossref PubMed Scopus (66) Google Scholar, 15de Vente J. Kiley S. Garris T. Bryant W. Hooker J. Posekany K. Parker P. Cook P. Fletcher D. Ways D.K. Cell Growth Differ. 1995; 6: 371-382PubMed Google Scholar, 16Chen C.Y. Faller D.V. Oncogene. 1995; 11: 1487-1498PubMed Google Scholar) have reported that TPA induces apoptosis in MCF-7 breast cancer cells, U937 cells, and Jurkat T-lymphoma cells. TPA is also known to modulate apoptosis induced by various agents (17Jarvis W.D. Povirk L.F. Turner A.J. Traylor R.S. Gewirtz D.A. Pettit G.R. Grant S. Biochem. Pharmacol. 1994; 47: 839-852Crossref PubMed Scopus (95) Google Scholar, 18Walker P.R. Kwast-Welfeld J. Gourdeau H. Leblanc J. Neugebauer W. Sikorska M. Exp. Cell Res. 1993; 207: 142-151Crossref PubMed Scopus (117) Google Scholar). However, the effects of TPA on induction of apoptosis seem to depend upon the type of cells; treatment of cells with inhibitors of PKC resulted in apoptosis in lymphocytes and HL60 cells, and TPA blocked apoptosis induced by VP-16 or interleukin withdrawal (18Walker P.R. Kwast-Welfeld J. Gourdeau H. Leblanc J. Neugebauer W. Sikorska M. Exp. Cell Res. 1993; 207: 142-151Crossref PubMed Scopus (117) Google Scholar, 19Lucas M. Sanchez-Margalet V. Sanz A. Solano F. Biochem. Pharmacol. 1994; 47: 667-672Crossref PubMed Scopus (45) Google Scholar, 20Jarvis W.D. Turner A.J. Povirk L.F. Traylor R.S. Grant S. Cancer Res. 1994; 54: 1707-1714PubMed Google Scholar, 21Rusnak J.M. Lazo J.S. Exp. Cell Res. 1996; 224: 189-199Crossref PubMed Scopus (39) Google Scholar). Studies have suggested that this different response to TPA in apoptosis is, in part, due to the existence of multiple PKC isotypes (22Cuvillier O. Rosenthal D.S. Smulson M.E. Spiegel S. J. Biol. Chem. 1998; 273: 2910-2916Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar, 23Mizuno K. Noda K. Araki T. Imaoka T. Kobayashi Y. Akita Y. Shimonaka M. Kishi S. Ohno S. Eur. J. Biochem. 1997; 250: 7-18Crossref PubMed Scopus (118) Google Scholar).Tumor necrosis factor-α (TNFα) is a pleiotropic cytokine that was originally identified on the basis of its ability to induce hemorrhagic necrosis in murine transplantable tumors and of its direct cytotoxic effects against transformed cells lines in vivo (24Carswell E.A. Old L.J. Kassel R.L. Green S. Fiore N. Williamson B. Proc. Natl. Acad. Sci. U. S. A. 1975; 72: 3666-3670Crossref PubMed Scopus (3723) Google Scholar, 25Helson L. Helson C. Green S. Exp. Cell Biol. 1979; 47: 53-60PubMed Google Scholar, 26Fransen L. Ruysschaert M.R. Van der Heyden J. Fiers W. Cell Immunol. 1986; 100: 260-267Crossref PubMed Scopus (88) Google Scholar). TNFα plays a physiological role in oncogeny and in the control of major inflammatory and immune reactions affecting both myelocytic and nonmyelocytic cells (27Fletcher J.R. Arch. Surg. 1993; 128: 1192-1196Crossref PubMed Scopus (46) Google Scholar). It is primarily produced by activated macrophages and exerts its effect through two distinct cell surface receptors, denoted TNFR1 and TNFR2. These two TNFα receptors are present on all nucleated cell types (28Hohmann H.P. Remy R. Brockhaus M. van Loon A.P. J. Biol. Chem. 1989; 264: 14927-14934Abstract Full Text PDF PubMed Google Scholar, 29Vandenabeele P. Declercq W. Vanhaesebroeck B. Grooten J. Fiers W. J. Immunol. 1995; 154: 2904-2913PubMed Google Scholar). TNFα preferentially kills transformed cells in vivo although it is not cytotoxic to normal diploid cells (26Fransen L. Ruysschaert M.R. Van der Heyden J. Fiers W. Cell Immunol. 1986; 100: 260-267Crossref PubMed Scopus (88) Google Scholar, 28Hohmann H.P. Remy R. Brockhaus M. van Loon A.P. J. Biol. Chem. 1989; 264: 14927-14934Abstract Full Text PDF PubMed Google Scholar, 29Vandenabeele P. Declercq W. Vanhaesebroeck B. Grooten J. Fiers W. J. Immunol. 1995; 154: 2904-2913PubMed Google Scholar). The mechanisms underlying the cytotoxic effects of TNFα are not completely understood. However, it has been shown that cytotoxicity of TNFα is mediated through mainly TNFR1, which has a 70-amino acid region in the cytoplasmic domain termed the “death domain” (30Van Antwerp D.J. Martin S.J. Verma I.M. Green D.R. Trends Cell Biol. 1998; 8: 107-111Abstract Full Text PDF PubMed Scopus (334) Google Scholar). Further studies have found that inhibition of DNA topoisomerase, production of reactive oxygen intermediates in the mitochondria, and induction of proteases appears to be involved (31Baloch Z. Cohen S. Coffman F.D. J. Immunol. 1990; 145: 2908-2913PubMed Google Scholar, 32Goossens V. Grooten J. De Vos K. Fiers W. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 8115-8119Crossref PubMed Scopus (553) Google Scholar, 33Suffys P. Beyaert R. Van Roy F. Fiers W. Eur. J. Biochem. 1988; 178: 257-265Crossref PubMed Scopus (62) Google Scholar). It has been reported that the cytotoxic effects of TNFα on neoplastic cells are synergistically enhanced by TPA in vitro although the molecular mechanisms underlying this synergism are not known (34Wang A.M. Creasey A.A. Ladner M.B. Lin L.S. Strickler J. Van Arsdell J.N. Yamamoto R. Mark D.F. Science. 1985; 228: 149-154Crossref PubMed Scopus (484) Google Scholar).In this study, we examined the cytotoxic effects of TPA on a human monocytic cell line, U937, and a human myeloblastic cell line, KY821. Our results demonstrate that TPA induces apoptosis through TNFα production in U937 and KY821 cells.DISCUSSIONThe development and maintenance of tissues are achieved by several dynamically regulated processes that include cell proliferation, differentiation, and programmed cell death (51Saunders Jr., J.W. Science. 1966; 154: 604-612Crossref PubMed Scopus (718) Google Scholar, 52Kerr J.F. Wyllie A.H. Currie A.R. Br. J. Cancer. 1972; 26: 239-257Crossref PubMed Scopus (12726) Google Scholar). When cells are exposed to external insults, negative regulation of the cell cycle or apoptosis occurs; cells which fail to repair DNA are eliminated through apoptosis (53Lotem J. Cragoe Jr., E.J. Sachs L. Blood. 1991; 78: 953-960Crossref PubMed Google Scholar, 54Imamura J. Miyoshi I. Koeffler H.P. Blood. 1994; 84: 2412-2421Crossref PubMed Google Scholar). In this study, we have investigated the mechanisms of apoptosis by a potent stimulator of PKC, TPA in the human monocytic cell line U937 and the myeloblastic cell line KY821. Our results show that TPA induces apoptosis, at least in part, through a pathway which requires endogenous production of TNFα in these cells.Our study showed that TPA stimulated production of TNFα in these cells, and pretreatment of cells with anti-TNFα neutralizing antibody abrogated apoptosis induced by TPA. Moreover, exogenously added TNFα also induced apoptosis in U937 cells. TPA also increased levels of IL-1β mRNA in U937cells. IL-1β is a cytokine, which is also produced by cells of monocytic lineage, and TNFα and IL-1β share a number of biological properties although they are molecularly distinct cytokines (55Le J. Vilcek J. Lab. Invest. 1987; 56: 234-248PubMed Google Scholar). However, treatment with anti-IL-1β antibody did not affect apoptosis induced by TPA. TNFα induces apoptosis through binding to TNFR1 (56Baker S.J. Reddy E.P. Oncogene. 1996; 12: 1-9PubMed Google Scholar). TNFR1 belongs to the same receptor family as Fas (APO/CD95) which is known to trigger apoptosis in a number of different cell types upon ligand binding (57Nagata S. Cell. 1997; 88: 355-365Abstract Full Text Full Text PDF PubMed Scopus (4537) Google Scholar). Studies have shown that both receptors contain an approximately 70-amino acid domain in the cytoplasmic region known as the “death domain,” which is required for the cytotoxic effects (58Itoh N. Nagata S. J. Biol. Chem. 1993; 268: 10932-10937Abstract Full Text PDF PubMed Google Scholar, 59Tartaglia L.A. Ayres T.M. Wong G.H. Goeddel D.V. Cell. 1993; 74: 845-853Abstract Full Text PDF PubMed Scopus (1162) Google Scholar). In this study, TPA increased levels of TNFR1 mRNA in U937 and KY821 cells. Moreover, the overexpression of TNFR1 enhanced the apoptosis induced by TPA in U937 cells whereas TPA did not affect levels of Fas. The cytotoxic effect of TNFα on neoplastic cells has been shown also to be synergistically enhanced by TPA in vitro (34Wang A.M. Creasey A.A. Ladner M.B. Lin L.S. Strickler J. Van Arsdell J.N. Yamamoto R. Mark D.F. Science. 1985; 228: 149-154Crossref PubMed Scopus (484) Google Scholar). Taken together, these results suggest that endogenous production of TNFα plays a crucial role in apoptosis of these cells.Death domain receptors including TNFR1 are constitutively expressed in various types of cells; these receptors are maintained in inactive state in the absence of ligands (60Jiang Y. Woronicz J.D. Liu W. Goeddel D.V. Science. 1999; 283: 543-546Crossref PubMed Scopus (343) Google Scholar, 61Tartaglia L.A. Goeddel D.V. Immunol. Today. 1992; 13: 151-153Abstract Full Text PDF PubMed Scopus (999) Google Scholar). Prior studies (60Jiang Y. Woronicz J.D. Liu W. Goeddel D.V. Science. 1999; 283: 543-546Crossref PubMed Scopus (343) Google Scholar) have suggested that it is difficult to generate stable cell lines overexpressing death domain receptors because the overexpression leads to receptor aggregation and constitutive apoptosis. We stably transfected U937 cells with a human TNFR1 expression vector and obtained several clones with different levels of TNFR1 mRNA. The most highly TNFR1-overexpressing U937 cells showed an approximately 6-fold TNFR1 level, as compared with that of control-transfected cells, with a slightly but significantly elevated basal level of apoptosis. A recent study has found a protein that protects against ligand-independent signaling by TNFR1 and other death domain receptors (60Jiang Y. Woronicz J.D. Liu W. Goeddel D.V. Science. 1999; 283: 543-546Crossref PubMed Scopus (343) Google Scholar). This protein, silencer of death domain (SODD), inhibits the intrinsic self-aggregation properties of the death domain and maintains TNFR1 in an active monomeric state; TNF reduces levels of silence of death domain bound to TNFR1 in U937 cells (60Jiang Y. Woronicz J.D. Liu W. Goeddel D.V. Science. 1999; 283: 543-546Crossref PubMed Scopus (343) Google Scholar). The mechanism responsible for the overexpression of TNFR1 in our U937 cells remains to be elucidated but may involve the expression of silence of death domain at a high level in these U937 cells.Recent studies have demonstrated that an activation of PKC-modulated apoptosis though results are contradictory; TPA induces apoptosis in certain cells including U937 cells but inhibits apoptosis induced by various agents including ceramide (18Walker P.R. Kwast-Welfeld J. Gourdeau H. Leblanc J. Neugebauer W. Sikorska M. Exp. Cell Res. 1993; 207: 142-151Crossref PubMed Scopus (117) Google Scholar, 21Rusnak J.M. Lazo J.S. Exp. Cell Res. 1996; 224: 189-199Crossref PubMed Scopus (39) Google Scholar, 22Cuvillier O. Rosenthal D.S. Smulson M.E. Spiegel S. J. Biol. Chem. 1998; 273: 2910-2916Abstract Full Text Full Text PDF PubMed Scopus (246) Google Scholar, 23Mizuno K. Noda K. Araki T. Imaoka T. Kobayashi Y. Akita Y. Shimonaka M. Kishi S. Ohno S. Eur. J. Biochem. 1997; 250: 7-18Crossref PubMed Scopus (118) Google Scholar, 62Shen S.C. Huang T.S. Jee S.H. Kuo M.L. Cell Growth Differ. 1998; 9: 23-29PubMed Google Scholar, 63Masuda Y. Yoda M. Ohizumi H. Aiuchi T. Watabe M. Nakajo S. Nakaya K. Int. J. Cancer. 1997; 71: 691-697Crossref PubMed Scopus (26) Google Scholar, 64Ferraris C. Cooklis M. Polakowska R.R. Haake A.R. Exp. Cell Res. 1997; 234: 37-46Crossref PubMed Scopus (47) Google Scholar). Other studies have also reported that activation of PKC by TPA prevented apoptosis induced by TNFα in U937 cells (65Cuvillier O. Pirianov G. Kleuser B. Vanek P.G. Coso O.A. Gutkind S. Spiegel S. Nature. 1996; 381: 800-803Crossref PubMed Scopus (1337) Google Scholar, 66Mayne G.C. Murray A.W. J. Biol. Chem. 1998; 273: 24115-24121Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar). These results suggest that whether apoptosis is induced in response to TPA depends on the type of cell. In this study, TPA induced apoptosis in U937 cells; these results were consistent with previous studies (15de Vente J. Kiley S. Garris T. Bryant W. Hooker J. Posekany K. Parker P. Cook P. Fletcher D. Ways D.K. Cell Growth Differ. 1995; 6: 371-382PubMed Google Scholar, 23Mizuno K. Noda K. Araki T. Imaoka T. Kobayashi Y. Akita Y. Shimonaka M. Kishi S. Ohno S. Eur. J. Biochem. 1997; 250: 7-18Crossref PubMed Scopus (118) Google Scholar). We also showed that TPA stimulated MAPK activity and inhibition of PKC or MAPK pathway almost completely prevented the production of TNFα and the induction of apoptosis by TPA. Activation of the MAPK signaling pathway via PKC is an important mechanism for several biological events such as apoptosis, and PKC regulates the MAPK pathway, alone or with other mechanisms (67Cobb M.H. Goldsmith E.J. J. Biol. Chem. 1995; 270: 14843-14846Abstract Full Text Full Text PDF PubMed Scopus (1657) Google Scholar,68Hall-Jackson C.A. Jones T. Eccles N.G. Dawson T.P. Bond J.A. Gescher A. Wynford-Thomas D. Br. J. Cancer. 1998; 78: 641-651Crossref PubMed Scopus (23) Google Scholar). Our results indicate that activation of the PKC and MAPK-signaling cascade leads to the accumulation of TNFα, which is required for the induction of apoptosis by TPA. However, much evidence accumulated suggests that TPA and TNFα exert opposing effects on the induction of apoptosis in U937 cells (60Jiang Y. Woronicz J.D. Liu W. Goeddel D.V. Science. 1999; 283: 543-546Crossref PubMed Scopus (343) Google Scholar).TNFα stimulates sphingomyelin degradation with the subsequent formation of ceramide, and ceramide induces apoptosis in leukemia cells (69Dressler K.A. Mathias S. Kolesnick R.N. Science. 1992; 255: 1715-1718Crossref PubMed Scopus (367) Google Scholar, 70Wiegmann K. Schutze S. Kampen E. Himmler A. Machleidt T. Kronke M. J. Biol. Chem. 1992; 267: 17997-18001Abstract Full Text PDF PubMed Google Scholar, 71Yanaga F. Watson S.P. FEBS Lett. 1992; 314: 297-300Crossref PubMed Scopus (57) Google Scholar, 72Obeid L.M. Linardic C.M. Karolak L.A. Hannun Y.A. Science. 1993; 259: 1769-1771Crossref PubMed Scopus (1598) Google Scholar, 73Dbaibo G.S. Obeid L.M. Hannun Y.A. J. Biol. Chem. 1993; 268: 17762-17766Abstract Full Text PDF PubMed Google Scholar, 74Jarvis W.D. Fornari F.A. Traylor R.S. Martin H.A. Kramer L.B. Erukulla R.K. Bittman R. Grant S. J. Biol. Chem. 1996; 271: 8275-8284Abstract Full Text Full Text PDF PubMed Scopus (142) Google Scholar, 75Ji L. Zhang G. Uematsu S. Akahori Y. Hirabayashi Y. FEBS Lett. 1995; 358: 211-214Crossref PubMed Scopus (164) Google Scholar). Moreover, there are reports that PKC activation is antagonistic to ceramide-induced apoptosis (64Ferraris C. Cooklis M. Polakowska R.R. Haake A.R. Exp. Cell Res. 1997; 234: 37-46Crossref PubMed Scopus (47) Google Scholar, 75Ji L. Zhang G. Uematsu S. Akahori Y. Hirabayashi Y. FEBS Lett. 1995; 358: 211-214Crossref PubMed Scopus (164) Google Scholar, 76Obeid L.M. Hannun Y.A. J. Cell. Biochem. 1995; 58: 191-198Crossref PubMed Scopus (235) Google Scholar). Also TPA has been shown to activate sphingosine kinase, leading to increased concentrations of sphingosine-1-phosphate (SPP), which is a metabolite of ceramide and suppresses ceramide-mediated apoptosis (65Cuvillier O. Pirianov G. Kleuser B. Vanek P.G. Coso O.A. Gutkind S. Spiegel S. Nature. 1996; 381: 800-803Crossref PubMed Scopus (1337) Google Scholar, 77Wu J. Spiegel S. Sturgill T.W. J. Biol. Chem. 1995; 270: 11484-11488Abstract Full Text Full Text PDF PubMed Scopus (182) Google Scholar). Furthermore, it has been demonstrated that blocking the MAPK pathway prevented the cytoprotective effect of SPP on TNFα-induced apoptosis in U937 cells (65Cuvillier O. Pirianov G. Kleuser B. Vanek P.G. Coso O.A. Gutkind S. Spiegel S. Nature. 1996; 381: 800-803Crossref PubMed Scopus (1337) Google Scholar). SPP stimulates MAPK activity and activation of MAPK promotes cell survival (77Wu J. Spiegel S. Sturgill T.W. J. Biol. Chem. 1995; 270: 11484-11488Abstract Full Text Full Text PDF PubMed Scopus (182) Google Scholar, 78Xia Z. Dickens M. Raingeaud J. Davis R.J. Greenberg M.E. Science. 1995; 270: 1326-1331Crossref PubMed Scopus (5027) Google Scholar). Taken together, these studies suggest that activation of MAPK may stimulate different pathways responsible for the opposing effects on apoptosis and cell survival.Leukemia cell lines including U937 and HL60 promyelomatic cells consist of phenotypically and biologically heterogeneous populations of cells that arrest at different stages of differentiation (79Ways D.K. Dodd R.C. Earp H.S. Cancer Res. 1987; 47: 3344-3350PubMed Google Scholar). A recent report has shown that certain PKC isotypes were down-regulated in differentiated cells (23Mizuno K. Noda K. Araki T. Imaoka T. Kobayashi Y. Akita Y. Shimonaka M. Kishi S. Ohno S. Eur. J. Biochem. 1997; 250: 7-18Crossref PubMed Scopus (118) Google Scholar). Although we provided evidence that TPA induced apoptosis through production of TNFα in U937 cells, the mechanism for the discrepancy between studies by other groups and us remains unclear. Studies suggest that the balance between the intracellular levels of ceramide and SPP is critical for the fate of cells (65Cuvillier O. Pirianov G. Kleuser B. Vanek P.G. Coso O.A. Gutkind S. Spiegel S. Nature. 1996; 381: 800-803Crossref PubMed Scopus (1337) Google Scholar, 66Mayne G.C. Murray A.W. J. Biol. Chem. 1998; 273: 24115-24121Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar). Considering these studies, the ceramide/SPP rheostat may be characteristic of cell type and, also, the differentiation-stage. Furthermore, the levels of products of PKC activation, TNFα, and SPP may be varied in each U937 cell line, leading to opposing effects on programmed cell death.Studies have shown that U937 cells have no wild type p53 transcripts or protein; a point mutation that converts G into A at the first base of intron 5 results in a partial deletion of 46 bases from the p53 mRNA (80Sugimoto K. Toyoshima H. Sakai R. Miyagawa K. Hagiwara K. Ishikawa F. Takaku F. Yazaki Y. Hirai H. Blood. 1992; 79: 2378-2383Crossref PubMed Google Scholar, 81Foti A. Bar-Eli M. Ahuja H.G. Cline M.J. Br. J. Haematol. 1990; 76: 143-145Crossref PubMed Scopus (38) Google Scholar). Our Western blot detected no p53 protein in U937 cells, and TPA did not induce p53. TNFα-induced apoptosis can occur in cells deficient for p53 or with mutated p53 (82Donato N.J. Perez M. J. Biol. Chem. 1998; 273: 5067-5072Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar). Thus, TNFα may be of critical importance for apoptosis in U937 cells that lack functional p53. Furthermore, in this study, untreated U937 cells constitutively underwent apoptosis to an extent. Moreover, the constitutive apoptosis was augmented by the overexpression of TNFR1 in these cells. Whereas the TNFα protein in the supernatant of untreated cells was below the level of undetectability, enzyme-linked immunosorbent assay showed that cell lysates of untreated U937 cells contained TNFα (0.39 μg/mg protein and 20 pg/106cells). Endogenously produced TNFα may induce apoptosis, in part, through autocrine loops in the endoplasmic reticulum. Apoptosis, a morphologically distinguished form of programmed cell death, plays important roles not only during development and tissue homeostasis but also in the pathogenesis of a variety of diseases including cancer, autoimmune disease, viral infection, and neurodegenerative disorder (1Raff M.C. Nature. 1992; 356: 397-400Crossref PubMed Scopus (2488) Google Scholar, 2Williams G.T. Smith C.A. Cell. 1993; 74: 777-779Abstract Full Text PDF PubMed Scopus (903) Google Scholar, 3Fisher D.E. Cell. 1994; 78: 539-542Abstract Full Text PDF PubMed Scopus (1368) Google Scholar, 4Martin S.J. Green D.R. Crit. Rev. Oncol. Hematol. 1995; 18: 137-153Crossref PubMed Scopus (154) Google Scholar, 5Thompson C.B. Science. 1995; 267: 1456-1462Crossref PubMed Scopus (6174) Google Scholar, 6White E. Genes Dev. 1996; 10: 1-15Crossref PubMed Scopus (1322) Google Scholar). Moreover, various chemicals and drugs for treatment of cancers are known to destroy tumor cells through apoptosis (7Eastman A. Curr. Opin. Oncol. 1990; 2: 1109-1114Crossref PubMed Scopus (11) Google Scholar, 8Miyashita T. Reed J.C. Blood. 1993; 81: 151-157Crossref PubMed Google Scholar). The precise mechanisms that control apoptosis have not been elucidated; it appears that this form of cell death is regulated by a genetic program involving both inducers and repressors (6White E. Genes Dev. 1996; 10: 1-15Crossref PubMed Scopus (1322) Google Scholar). The tumor suppressor p53 is one of the key proteins affecting the fate of cells exposed to external insults; activation of p53 leads to apoptosis or cell cycle arrest. Inactivation of p53 by either a mutation of the gene or interaction with oncogenic viral or cellular proteins is a common event in the development of malignancies (9Nigro J.M. Baker S.J. Preisinger A.C. Jessup J.M. Hostetter R. Cleary K. Bigner S.H. Davidson N. Baylin S. Devilee P. Glover T. Collins F.S. Weston A. Modali R. Harris C.C. Vogelstein B. Nature. 1989; 342: 705-708Crossref PubMed Scopus (2553) Google Scholar). On the other hand, recent studies have found pathways of apoptosis independent of p53 (10Yonish-Rouach E. Experientia. 1996; 52: 1001-1007Crossref PubMed Scopus (57) Google Scholar). Protein kinase C (PKC) 1The abbreviations used are:PKCprotein kinase CTPA12-O-tetradecanoylphorbol-13-acetateTNFαtumor necrosis factor-αIL-1βinterleukin-1βTNFR1TNF receptor 1MAPKmitogen-activated protein kinaseERKextracellular signal-regulated protein kinaseMEKmitogen-activated/extracellular-regulated kinasekbkilobase(s)SPPsphingosine-1-phosphateRbretinoblastoma susceptibility gene product 1The abbreviations used are:PKCprotein kinase CTPA12-O-tetradecanoylphorbol-13-acetateTNFαtumor necrosis factor-αIL-1βinterleukin-1βTNFR1TNF receptor 1MAPKmitogen-activated protein kinaseERKextracellular signal-regulated protein kinaseMEKmitogen-activated/extracellular-regulated kinasekbkilobase(s)SPPsphingosine-1-phosphateRbretinoblastoma susceptibility gene product plays important roles in physiological events such as cell differentiation and proliferation (11Weinstein I.B. Cancer Res. 1988; 48: 4135-4143PubMed Google Scholar). PKC phosphorylates and activates Raf-1, which leads to the activation of mitogen-activated protein kinase (MAPK) or extracellular signal-regulated protein kinase (ERK) (12Kolch W. Heidecker G. Kochs G. Hummel R. Vahidi H. Mischak H. Finkenzeller G. Marme D. Rapp U.R. Nature. 1993; 364: 249-252Crossref PubMed Scopus (1153) Google Scholar). By contrast, studies have shown that proliferation of cells is also inhibited by PKC activation; phorbol esters that can activate PKC have been shown to inhibit the phosphorylation of retinoblastoma susceptibility gene product (Rb) (13Sasaguri T. Ishida A. Kosaka C. Nojima H. Ogata J. J. Biol. Chem. 1996; 271: 8345-8351Abstract Full Text Full Text PDF PubMed Scopus (41)" @default.
• W2056377426 created "2016-06-24" @default.
• W2056377426 creator A5020868689 @default.
• W2056377426 creator A5028290908 @default.
• W2056377426 creator A5054408940 @default.
• W2056377426 creator A5055804570 @default.
• W2056377426 creator A5058282779 @default.
• W2056377426 creator A5082261779 @default.
• W2056377426 creator A5084670434 @default.
• W2056377426 date "1999-10-01" @default.
• W2056377426 modified "2023-10-18" @default.
• W2056377426 title "12-O-tetradecanoylphorbol-13-acetate-induced Apoptosis Is Mediated by Tumor Necrosis Factor α in Human Monocytic U937 Cells" @default.
• W2056377426 cites W1491611834 @default.
• W2056377426 cites W1499321844 @default.
• W2056377426 cites W1552669957 @default.
• W2056377426 cites W1577393853 @default.
• W2056377426 cites W1580617714 @default.
• W2056377426 cites W1591166893 @default.
• W2056377426 cites W1594159276 @default.
• W2056377426 cites W1620348927 @default.
• W2056377426 cites W1693778124 @default.
• W2056377426 cites W1964390988 @default.
• W2056377426 cites W1965041925 @default.
• W2056377426 cites W1966565183 @default.
• W2056377426 cites W1966944691 @default.
• W2056377426 cites W1967439648 @default.
• W2056377426 cites W1969785844 @default.
• W2056377426 cites W1970044546 @default.
• W2056377426 cites W1971448678 @default.
• W2056377426 cites W1973248926 @default.
• W2056377426 cites W1973331210 @default.
• W2056377426 cites W1976384164 @default.
• W2056377426 cites W1976385326 @default.
• W2056377426 cites W1977707442 @default.
• W2056377426 cites W1979046763 @default.
• W2056377426 cites W1979841881 @default.
• W2056377426 cites W1982213879 @default.
• W2056377426 cites W1983582864 @default.
• W2056377426 cites W1989783048 @default.
• W2056377426 cites W1991320440 @default.
• W2056377426 cites W1991865867 @default.
• W2056377426 cites W1996532068 @default.
• W2056377426 cites W1998145026 @default.
• W2056377426 cites W2002503549 @default.
• W2056377426 cites W2006127629 @default.
• W2056377426 cites W2013052118 @default.
• W2056377426 cites W2014669590 @default.
• W2056377426 cites W2017729786 @default.
• W2056377426 cites W2022589671 @default.
• W2056377426 cites W2024232113 @default.
• W2056377426 cites W2035666205 @default.
• W2056377426 cites W2039803453 @default.
• W2056377426 cites W2046878399 @default.
• W2056377426 cites W2048675234 @default.
• W2056377426 cites W2049496426 @default.
• W2056377426 cites W2049808548 @default.
• W2056377426 cites W2051037631 @default.
• W2056377426 cites W2052853635 @default.
• W2056377426 cites W2054050890 @default.
• W2056377426 cites W2054549064 @default.
• W2056377426 cites W2056500157 @default.
• W2056377426 cites W2057123987 @default.
• W2056377426 cites W2064508977 @default.
• W2056377426 cites W2068502127 @default.
• W2056377426 cites W2071055800 @default.
• W2056377426 cites W2072349044 @default.
• W2056377426 cites W2078003307 @default.
• W2056377426 cites W2083735475 @default.
• W2056377426 cites W2091536410 @default.
• W2056377426 cites W2092516221 @default.
• W2056377426 cites W2093676869 @default.
• W2056377426 cites W2106410559 @default.
• W2056377426 cites W2120412754 @default.
• W2056377426 cites W2150571795 @default.
• W2056377426 cites W2150912846 @default.
• W2056377426 cites W2158630493 @default.
• W2056377426 cites W2166622998 @default.
• W2056377426 cites W2169378309 @default.
• W2056377426 cites W2437351780 @default.
• W2056377426 cites W4231615136 @default.
• W2056377426 cites W4293247451 @default.
• W2056377426 doi "https://doi.org/10.1074/jbc.274.40.28286" @default.
• W2056377426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10497185" @default.
• W2056377426 hasPublicationYear "1999" @default.
• W2056377426 type Work @default.
• W2056377426 sameAs 2056377426 @default.
• W2056377426 citedByCount "28" @default.
• W2056377426 countsByYear W20563774262013 @default.
• W2056377426 countsByYear W20563774262014 @default.
• W2056377426 countsByYear W20563774262015 @default.
• W2056377426 crossrefType "journal-article" @default.
• W2056377426 hasAuthorship W2056377426A5020868689 @default.
• W2056377426 hasAuthorship W2056377426A5028290908 @default.
• W2056377426 hasAuthorship W2056377426A5054408940 @default.
• W2056377426 hasAuthorship W2056377426A5055804570 @default.
• W2056377426 hasAuthorship W2056377426A5058282779 @default.
• W2056377426 hasAuthorship W2056377426A5082261779 @default.
• W2056377426 hasAuthorship W2056377426A5084670434 @default.

• next